Business Context and Reporting Period
Company: Daxor Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and the Volumex radiopharmaceutical kit. It also operates Scientific Medical Systems, a subsidiary providing cryobanking services for blood and semen (Idant). The company relies heavily on investment income to offset operating losses.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Operating Revenues | $1,869,779 | $1,486,449 |
| Loss from Operations | $(5,430,870) | $(5,424,921) |
| Net Income (Loss) | $10,647,216 | $(785,531) |
| Investment Income (Net) | $17,389,110 | $4,651,140 |
| Total Assets | $102,560,500 | $78,166,312 |
| Total Liabilities | $47,644,615 | $32,528,520 |
| Stockholders' Equity | $54,915,885 | $45,637,792 |
| Cash and Cash Equivalents | $2,029,834 | $2,838,927 |
Segment Performance:
- Equipment Sales & Related Services: Revenue of $1,453,201 (up from $1,055,706). Sold 6 analyzers vs. 2 in 2006.
- Cryobanking: Revenue of $416,578 (down 3.3% from 2006).
Material Changes vs. Prior Period
- Net Income Surge: The company reported a net income of $10.6 million in 2007 compared to a net loss of $0.8 million in 2006. This reversal was driven almost entirely by a $14.9 million gain on the sale of investments (vs. $3.3 million in 2006), rather than operational performance.
- Operating Loss Persistence: Despite revenue growth, the operating loss remained flat at approximately $5.4 million due to high R&D ($2.6M) and SG&A ($4.0M) expenses.
- Asset Growth: Total assets increased by $24.4 million, primarily due to the appreciation of the investment portfolio (market value rose to $74.9M) and the acquisition of a manufacturing facility in Oak Ridge, Tennessee.
- Liabilities: Short-term debt increased significantly to $47.2 million, largely due to a rise in "Securities borrowed" (short positions) from $10.7M to $20.4M and a new deferred tax liability of $15.7M.
Guidance, Outlook, Risks, and Contingencies
Reimbursement Risk (Critical): The Centers for Medicare and Medicaid Services (CMS) implemented a policy change effective January 1, 2008, eliminating separate reimbursement for diagnostic radiopharmaceuticals (Volumex) for outpatient services. Hospitals must now absorb the cost of the kit. Management states the impact on 2008 revenue is currently unquantifiable.
SEC Investigation: The SEC has recommended action against the Company and CEO Dr. Joseph Feldschuh for potential violations of the Investment Company Act. The Company maintains it is an operating company, not an investment company, but the outcome and potential penalties are uncertain.
Customer Concentration: Three hospital customers accounted for 32% of total consolidated sales in 2007. The loss of any single customer could adversely affect the business.
Key Personnel: The Company is significantly dependent on Dr. Joseph Feldschuh (CEO/Chief Scientist) for both scientific direction and investment management.
Outlook: Management believes current liquidity is adequate for immediate needs but notes that raising additional capital may be difficult without significant dilution. The company is focused on transitioning the BVA-100 from research to widespread clinical use.
Investor Verification Checklist
- Investment vs. Operations: Verify the sustainability of the $10.6M net income, which is derived from investment gains rather than core medical device sales.
- CMS Policy Impact: Assess the potential revenue reduction from the 2008 CMS reimbursement change regarding Volumex kits.
- SEC Status: Monitor the status of the SEC recommendation regarding the Investment Company Act violation.
- Customer Concentration: Review the stability of the three major hospital customers representing nearly one-third of sales.
- Short Positions: Analyze the risk exposure associated with the $20.4M in securities borrowed (short positions) and the associated mark-to-market volatility.